Compass Pathways plc (CMPS) — Compass Pathways released 26-week (Part B) results from COMP006, its second pivotal Phase 3 trial of COMP360 synthetic psilocybin in treatment-resistant depression.
About 39% of patients in the 25 mg arm achieved a clinically meaningful MADRS reduction by Week 6 and maintained a durable response through Week 26, while nearly 30% of Week 6 responders went into remission after retreatment. The company said its rolling FDA NDA submission is underway with final submission on track for Q4 2026 and a potential launch in the first half of 2027, subject to approval and DEA rescheduling.
Source: businesswire.com
For the rest of that week's sector news, read our week in review.